Zimmer Biomet Holdings ((ZBH)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Zimmer Biomet Holdings is conducting a study titled Concordance Between an App-based Range of Motion Measurement and Standard Goniometer. The study aims to evaluate how well the mymobility knee ROM app measures knee range of motion compared to traditional clinician assessments using a goniometer. This research is significant as it could validate a more accessible, app-based method for assessing knee mobility.
Intervention/Treatment: The study tests the mymobility knee ROM app, designed to measure knee range of motion. The app’s results will be compared to those obtained by clinicians using a standard goniometer, a tool commonly used in physical assessments.
Study Design: This is an observational study with a cohort model and a prospective time perspective. Participants will have their knee range of motion measured three times: once using the mymobility app and twice using a goniometer by two different assessors. The assessors will be blinded to each other’s measurements to ensure unbiased results.
Study Timeline: The study was first submitted on March 3, 2025, and the latest update was submitted on September 4, 2025. The study is not yet recruiting, indicating that it is in the early stages of preparation.
Market Implications: The successful validation of the mymobility app could enhance Zimmer Biomet’s market position by offering a new, tech-driven solution for knee assessments. This could positively influence the company’s stock performance and investor sentiment, especially as digital health solutions gain traction. Competitors in the orthopedic and digital health sectors may need to innovate similarly to stay competitive.
The study is ongoing, with further details available on the ClinicalTrials portal.